RecruitingNCT04612075

The EMINENCE Study - PET/MR Imaging of Head Neck Cancer


Sponsor

Norwegian University of Science and Technology

Enrollment

390 participants

Start Date

Jan 12, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Head and neck cancers (HNC) often receive radiotherapy as part of their treatment. However, unacceptable failure rates and severe side effects remain a challenge. The improvements in radiotherapy are closely related to improvements in medical imaging. Functional imaging, where intratumoural characteristics such as tumour oxygenation, metabolism, and blood vessel function can be quantified, offers possibilities to personalize the radiotherapy. In this study we will establish the clinical workflow for PET- and MRI-based radiotherapy in HNC by acquiring images prior to and during radiotherapy to develop new concepts for image-based biologically adaptive radiotherapy, both based on photon-based radiotherapy and also proton therapy, which soon will be available for cancer patients in Norway. The investigators aim to contribute towards further developments of personalised high-precision radiotherapy for HNC patients resulting in improved outcome, reduced side-effects and better quality of life.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (called EMINENCE) is using a specialized combined PET/MRI scan to better understand how head and neck cancers use oxygen and nutrients during radiation therapy. The goal is to improve how doctors plan and adjust radiation treatment in real time. **You may be eligible if...** - You have been confirmed by biopsy to have squamous cell carcinoma of the head and neck (throat, voice box, mouth, or sinuses) - You have locally advanced disease (stages T3/T4 or with lymph node involvement) without distant spread - You are scheduled for definitive radiation therapy, with or without chemotherapy - Your kidney function is adequate - You are willing and able to give informed consent **You may NOT be eligible if...** - You have a contraindication to MRI (e.g., certain metal implants) - You are allergic to MRI contrast agents - You are pregnant or breastfeeding - You have distant metastases Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFDG-PET/MRI

Performed at baseline, interim and at 12-16 weeks post radiotherapy.


Locations(2)

University Hospital of North Norway

Tromsø, Norway

St Olavs Hospital, Department of Oncology

Trondheim, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04612075


Related Trials